Urine Klotho Is Lower in Critically Ill Patients With Versus Without Acute Kidney Injury and Associates With Major Adverse Kidney Events

Javier A. Neyra, MD, MSCS1,2,3; Xilong Li, PhD4; Federica Mescia, MD2; Victor Ortiz-Soriano, MD1; Beverley Adams-Huet, MS5; Johanne Pastor, BS2; Ming-Chang Hu, MD, PhD2,3; Robert D. Toto, MD3,4; Orson W. Moe, MD2,3,5; for the Klotho and Acute Kidney Injury (KLAKI) Study Group

1Division of Nephrology, Bone and Mineral Metabolism, Department of Internal Medicine, University of Kentucky, Lexington, KY. 2Charles and Jane Pak Center for Mineral Metabolism and Clinical Research, Dallas, TX. 3Division of Nephrology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX. 4Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX. 5Department of Physiology, University of Texas Southwestern Medical Center, Dallas, TX.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (http://journals.lww.com/ccejournal).

Supported, in part, by the University of Texas Southwestern Medical Center O’Brien Kidney Research Core Center (P30 DK079328-06), the National Center for Advancing Translational Sciences (UL1TR001105), and the National Institutes of Health (R01 DK092461-04S1). The content is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health or the University of Texas Southwestern.

Dr. Neyra was supported by the Ben J. Lipps Research Fellowship Program of American Society of Nephrology Foundation for Kidney Research, the Truelson Fellowship Fund, and the Seldin-Pak Center of Metabolic Research at University of Texas Southwestern Charles and Jane Pak Center of Mineral Metabolism and Clinical Research. He is currently supported by an Early Career Pilot Grant from the National Center for Advancing Translational Sciences, National Institutes of Health, through grant UL1TR001998. The remaining authors have disclosed that they do not have any potential conflicts of interest.

Drs. Neyra, Toto, and Moe helped with study concept and design. Drs. Neyra and Mescia helped with patient screening, recruitment, and biospecimen collections. Ms. Pastor helped with sample processing and biomarker measurements. Drs. Neyra, Hu, Toto, and Moe helped with analysis and interpretation of data. Dr. Neyra helped with drafting of the manuscript. Drs. Neyra, Hu, Toto, and Moe helped with critical revision of the manuscript for important intellectual content. Drs. Li, Ortiz-Soriano, and Adams-Huet helped with statistical analysis. Drs. Neyra, Toto, and Moe helped with administrative, technical, and material support. Drs. Neyra and Moe helped with study supervision.

For information regarding this article, E-mail: javier.neyra@uky.edu

Copyright © 2019 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Crit Care Explor 2019; 1:e0016
DOI: 10.1097/CCE.0000000000000016
acute kidney injury (AKI) is a detrimental syndrome that occurs in approximately 50% of critically ill patients admitted to ICUs (1, 2). AKI is associated with high morbidity, mortality (3, 4), and risk of chronic kidney disease (CKD) (5, 6) and end-stage renal disease (ESRD) (7). Discovery and validation of AKI biomarkers have mostly focused on early AKI recognition (8, 9), and little is known about their utility to predict AKI recovery or subsequent CKD/ESRD risk post-AKI. Kidney function examination within 90 days postsudosis in survivors of AKI associates with subsequent risk of ESRD and has been proposed as a surrogate endpoint for ESRD after AKI (10).

αKlotho (referred to as “Klotho”) is primarily expressed in the kidney (11) and has emerged as a potential therapeutic agent for AKI in preclinical studies (12). Transmembrane Klotho is a coreceptor for fibroblast growth factor (FGF)-23. The extracellular domain of transmembrane Klotho is cleaved by proteases (13–15) and released into the circulation (soluble Klotho) and can be measured in blood and urine (16, 17). Soluble Klotho is not filtered by the glomerulus, but traffics via transcytosis across the renal tubules, from the basolateral to the luminal side, exerts actions in the urine, and is then excreted in the urine (17). Preclinical data have shown that Klotho protein replacement or transgenic overexpression (18–20) can attenuate AKI, promote recovery, and prevent CKD post-AKI (18, 21).

Elevation of plasma FGF23 levels has been described in AKI (22, 23) and associates with adverse outcomes post-AKI in critically ill and cardiac surgery patients (24–26). Impaired renal clearance or increased production from bone or other organs is potential origins of this elevation (27).

The purpose of the present study was to examine whether urine Klotho and serum intact FGF23 levels are different in critically ill patients with versus without AKI and if these biomarker levels associate with major adverse kidney events (MAKE). To our knowledge, this is the first study in critically ill patients in which concomitant measurements of urine Klotho and serum intact FGF23 levels were done.

METHODS

Study Design and Participants

Single-center, prospective study of 54 AKI patients and 52 matched controls without AKI admitted to the ICU at the University of Texas Southwestern Hospital from January 2015 to January 2016. AKI was defined by Kidney Disease: Improving Global Outcomes (KDIGO) criteria (28). Only patients with AKI stage greater than or equal to 2 were included in the study as cases. Controls were frequency matched by age (10-yr intervals), gender, and two-category baseline estimated glomerular filtration rate (eGFR, calculated using CKD-Epidemiology Collaboration (CKD-EPI) equation, ≥ 90 and 60–89 mL/min/1.73 m²) (29). Baseline serum creatinine (SCr) was defined as the most recent SCr within the 6-month period before ICU admission.

Inclusion criteria included the following: adults greater than or equal to 18 years old, admission to the ICU, and baseline eGFR greater than or equal to 60 mL/min/1.73 m². Exclusion criteria consisted of prior kidney or any other solid organ transplant, ESRD, evidence of AKI before ICU admission, or the presence of uroepithelial tumors. The protocol was approved by the Institutional Review Board. Informed consent was obtained for all study participants.

Sample Collection

A single-timepoint paired serum and urine samples were obtained 24–48 hours after AKI diagnosis (cases) or ICU admission (controls). Standardized techniques for serum and urine collection, transport, processing, and storage were employed. Biospecimens were centrifuged at 1,000g, 4°C for 10 minutes. Serum and urine supernatant were aliquoted in coded nonsiliconized cryovials and stored at −80°C until biomarker measurements were done by laboratory personnel blinded to the study design and data. Urine samples were not obtained in seven patients due to anuria.

Laboratory Analyses

Urine Klotho was measured by immunoblotting urine with monoclonal anti-Klotho antibody KM2076 (TransGenic, Kobe, Japan) with calibration against Klotho standards (30). Urine Klotho was normalized to creatinine concentration in the same spot urine sample. The intra-assay coefficient of variation is 8%. Serum intact FGF23 was measured using the human Intact FGF23 Enzyme-Linked Immunosorbent Assay kit (Immutopics-Quidel, San Diego, CA). Urine creatinine was measured by capillary electrophoresis (31). Other reported analytes were measured as part of standard of care.

Clinical Data

Data pertaining to demographics, kidney function, comorbidity, Charlson index, and critical illness parameters were obtained. Acute Physiology and Chronic Health Evaluation (APACHE) II and Sequential Organ Failure Assessment (SOFA) scores were calculated integrating data from the first day of ICU admission. For both APACHE II and SOFA, the points related to SCr were subtracted from the total score. Anemia was defined as admission hematocrit less than 39% for men and less than 36% for women.

Study Outcome

The observation period was from study enrollment until death or 90 days for survivors. The primary outcome was 90-day MAKE, which consisted of the composite of all-cause death, renal replacement therapy (RRT) dependence, or the decrease in eGFR of greater than or equal to 50% from baseline (32). Secondary outcomes consisted of mechanical ventilation days and hospital days and were examined only inhospital survivors to offset the competing risk of death.
Statistical Analysis
Categorical data were reported as percentages, and continuous
data were reported as means ± SD or median (25th–75th percent-
tile). Comparisons across biomarker tertiles for categorical vari-
ables were made using Fisher exact test. For continuous variables,
analysis of variance was used for Gaussian and Kruskal–Wallis test
for non-Gaussian distributed data. Comparisons between AKI
versus no-AKI and MAKE-90 versus no MAKE-90 for categori-
variables were made using Fisher exact test. For continuous
variables, t test was used for Gaussian and Wilcoxon rank-sum
test for non-Gaussian distributed data. Biomarker data were non-
Gaussian distributed and were therefore natural log transformed.

Multivariable logistic regression models were constructed for
MAKE-90 as the dependent variable and to evaluate the following
biomarkers as independent variables: urine Klotho, urine Klotho
adjusted by urinary creatinine (urine Klotho/creatinine), serum intact FGF23, and serum intact FGF23 divided by urinary Klotho
adjusted by urinary creatinine (FGF23-to-Klotho/creatinine ratio).
Model 1 included age, sex, and Charlson index. Model 2 included
variables in Model 1 plus nonrenal APACHE II score. Only one
of two acuity of illness scores (APACHE II or SOFA) was included
due to collinearity between variables. Secondary outcomes (hos-
pital days and mechanical ventilation days) were examined only
in those who survived the hospitalization utilizing negative bino-
mial regression adjusted for Model 2. The two-way interaction
between AKI status and each study biomarker for its association
with MAKE-90 was evaluated and found to be nonsignificant
(p > 0.1 for all biomarkers).

Spearman correlation analysis was performed for each study
biomarker and preselected biochemical parameters measured less
than 48 hours apart from the study biomarkers. Two-sided p val-
ues of less than 0.05 indicated statistical significance. SAS 9.4 (SAS
Institute, Cary, NC) was used for statistical analyses.

Sensitivity Analyses
We examined an alternative and more sensitive definition for the
primary outcome of MAKE-90, which consisted of the composite
of all-cause death, RRT dependence, or the decrease in eGFR of
greater than or equal to 25% from baseline (rather than 50%) (32).

RESULTS
Clinical Characteristics
A total of 106 patients were included in the study, 54 with AKI
stage greater than or equal to 2 and 52 without AKI (controls).
When comparing characteristics according to tertiles of urine
Klotho/creatinine, we observed that patients in the lowest tertile
of urine Klotho/creatinine had more frequently diabetes, ane-
mia, and dipstick proteinuria greater than or equal to 30 mg/dL.
Concordantly, patients in the lowest tertile of urine Klotho/cre-
atinine had higher Charlson index scores and higher SOFA and
APACHE II scores, along with worse critical illness parameters
when compared with their counterparts (Table 1). As depicted in
Supplementary Table 1 (Supplemental Digital Content 1, http://
links.lww.com/CCX/A52), patients in the highest tertile of FGF23
had more frequently anemia and dipstick proteinuria greater
than or equal to 30 mg/dL, higher Charlson scores, and higher
APACHE II scores.

Characteristics according to AKI status are reported in
Supplementary Table 2 (Supplemental Digital Content 2, http://
links.lww.com/CCX/A53). There were no differences in age,
gender, or baseline eGFR as per study design. However, patients
with AKI had more frequently anemia, liver disease, and higher
Charlson scores. Similarly, patients with AKI had higher SOFA
and APACHE II scores along with worse critical illness param-
eters when compared with those without AKI.

Study Outcomes
A total of 44 patients (41.5%) developed MAKE-90: 33 (75%) died,
three (6.8%) became RRT dependent, and eight (18.2%) survived,
were RRT independent but had a decrease in eGFR of greater
than or equal to 50% from baseline by 90 days postenrollment.
Patients in whom MAKE-90 developed had higher Charlson
scores and higher critical illness scores (Supplementary Table 3,
Supplemental Digital Content 3, http://links.lww.com/CCX/A54).
MAKE-90 occurred more frequently in patients who suffered
from AKI (70.4% vs 29.6%; p < 0.0001).

Study Biomarkers According to AKI Status
Urine Klotho (pM) and urine Klotho/creatinine (fmol/mg of cre-
atinine) levels were significantly lower in patients with AKI versus
without AKI (median [25th–75th percentile], 6.0 [4.9–45.0] vs
23.0 [5.0–67.4]; p < 0.0001; and 9.2 [3.0–33.6] vs 25.0 [6.0–92.8];
p < 0.0001, respectively). Serum intact FGF23 (pg/mL) was sig-
nificantly higher in patients with AKI versus without AKI (139.4
[10.5–4.844.4] vs 17.4 [4.9–196.0]; p < 0.0001). Similarly, FGF23-
to-Klotho/creatinine ratios were significantly higher in patients
with AKI versus without AKI (Fig. 1).

Association of Study Biomarkers With MAKE-90
Urine Klotho (pM) and urine Klotho/creatinine (fmol/mg of cre-
atinine) levels were significantly lower in patients who had MAKE-
90 versus those who did not (median [25th–75th percentile], 6.0
[4.9–54.6] vs 19.0 [4.9–67.4]; p = 0.0008; and 8.4 [3.0–28.7] vs
21.2 [4.7–92.8]; p < 0.0001, respectively). Serum intact FGF23
(pg/mL) was significantly higher in patients who had versus who
did not have MAKE-90 (89.2 [4.9–3,151.0] vs 22.9 [4.9–4,844.4];
p = 0.0004). Similarly, FGF23-to-Klotho/creatinine ratios were
significantly higher in patients who had versus who did not have
MAKE-90 (Fig. 1).

In adjusted models, each one-fold higher urine Klotho/creati-
nine levels was associated with an 83% (95% CI, 60–93%) lower
risk of developing MAKE-90. In contrast, each one-fold higher
serum intact FGF23 levels was associated with a 90% (95% CI,
17–210%) higher risk of developing MAKE-90. Similarly, each
one-fold increase in the FGF23-to-Klotho/creatinine ratio was
associated with a 172% (95% CI, 49–396%) higher risk of develop-
ing MAKE-90 (Table 2). When biomarker levels were stratified in
tertiles, the highest tertile of urine Klotho/creatinine (vs the low-
est tertile) was independently associated with a 95% (95% CI, 75–
99%) lower risk of developing MAKE-90. In contrary, the highest
tertile of both serum intact FGF23 and the FGF23-to-Klotho/
creatinine ratio (vs the lowest tertile) was associated with higher risk of MAKE-90 (Table 2 and Fig. 2).

There was no statistical interaction between the AKI status and the association between the study biomarkers and MAKE-90 ($p > 0.1$ for each biomarker). Notably, urine Klotho/creatinine was the only biomarker significantly associated with MAKE-90 in patients with AKI (Supplementary Table 4, Supplemental Digital Content 4, http://links.lww.com/CCX/A55). There were 16 patients (25.8%) who had AKI but did not develop MAKE-90. In these patients, urine Klotho/creatinine was significantly higher and serum intact FGF23 lower, when compared with those who developed MAKE-90 (median [25th–75th percentile], 26.3 [12.4–92.8] vs 8.4 [3.0–28.7]; $p < 0.0001$; and 17.4 [4.9–196.0] vs 89.2 [4.9–3,151.0]; $p < 0.0001$, respectively).

### Association of Study Biomarkers With Secondary Outcomes

In adjusted models, urine Klotho and urine Klotho/creatinine levels were inversely correlated with total hospital days and mechanical ventilation days in hospital survivors. In contrast, serum intact

---

**TABLE 1. Characteristics of Patients According to Tertiles of Urine Klotho/Creatinine**

| Characteristic                                      | Tertile 1 | Tertile 2 | Tertile 3 | $p$  |
|-----------------------------------------------------|-----------|-----------|-----------|------|
| Range, fmol/mg                                       | $\leq 11.4$ | 11.7–21.2 | 22.3–92.8 | 0.16 |
| No. of patients                                      | 33        | 33        | 33        |      |
| Demographics                                        |           |           |           |      |
| Age, yr $\pm$ sd                                     | $56.9 \pm 17.3$ | $61.0 \pm 14.6$ | $53.5 \pm 15.3$ | 0.16 |
| Women, n (%)                                         | 16 (48.5) | 11 (33.3) | 15 (45.5) | 0.44 |
| White race, n (%)                                    | 23 (69.7) | 22 (66.7) | 24 (72.7) | 0.77 |
| Body mass index, kg/m², yr $\pm$ sd                  | $30.4 \pm 9.8$ | $27.5 \pm 6.8$ | $27.3 \pm 7.5$ | 0.23 |
| Baseline kidney function                             |           |           |           |      |
| Estimated glomerular filtration rate (Chronic Kidney Disease Epidemiology Collaboration equation), mL/min/1.73 m², median (IQR) | $90.2 (70.1–100.2)$ | $91.9 (78.9–100.2)$ | $96.6 (83.7–103.0)$ | 0.49 |
| SCr, mg/dL, median (IQR)                             | $0.9 (0.7–1.0)$ | $0.9 (0.6–1.0)$ | $0.9 (0.7–1.0)$ | 0.82 |
| Dipstick proteinuria $> 30$ mg/dL, n (%)              | 24 (72.7) | 11 (33.3) | 7 (21.2) | < 0.0001 |
| Comorbidity                                          |           |           |           |      |
| Diabetes, n (%)                                      | 13 (39.4) | 6 (18.2)  | 6 (18.2)  | 0.09 |
| Hypertension, n (%)                                   | 20 (60.6) | 16 (48.5) | 19 (57.6) | 0.67 |
| Congestive heart failure, n (%)                       | 11 (33.3) | 10 (30.3) | 9 (27.3)  | 0.96 |
| Chronic obstructive pulmonary disease, n (%)          | 6 (18.2)  | 3 (9.1)   | 6 (18.2)  | 0.54 |
| Liver disease, n (%)                                  | 11 (33.3) | 6 (18.2)  | 4 (12.1)  | 0.14 |
| Anemia, n (%)                                         | 29 (87.9) | 18 (54.6) | 23 (69.7) | 0.01 |
| Cancer, n (%)                                         | 15 (45.5) | 16 (50.0) | 14 (42.4) | 0.85 |
| Charlson index, median (IQR)                          | 5 (2–8)   | 3 (2–5)   | 2 (2–4)   | 0.008|
| Critical illness parameters                          |           |           |           |      |
| CFB 72 hr, L, median (IQR)                            | $5.0 (2.1–8.0)$ | $1.7 (–0.1 to 4.3)$ | $1.0 (–0.3 to 2.9)$ | 0.004|
| CFB ICU stay, L, median (IQR)                         | $8.5 (0.9–14)$ | $1.7 (–0.1 to 4.6)$ | $1.0 (–2 to 3.5)$ | 0.003|
| Pressor or inotrope, n (%)                            | 21 (63.6) | 14 (42.4) | 11 (33.3) | 0.04 |
| Mechanical ventilation, n (%)                         | 22 (66.7) | 15 (45.5) | 11 (33.3) | 0.03 |
| Packed RBC transfusion, n (%)                         | 21 (63.6) | 13 (39.4) | 9 (27.3)  | 0.01 |
| Nonrenal Acute Physiology and Chronic Health Evaluation II score (the points related to SCr were subtracted from the total score), median (IQR) | $18 (15–22)$ | $18 (12–20)$ | $11 (7–17)$ | 0.004|
| Nonrenal Sequential Organ Failure Assessment score (the points related to SCr were subtracted from the total score), median (IQR) | $8 (4–11)$ | $6 (1–8)$ | $2 (1–6)$ | 0.0008|
FGF23 and the FGF23-to-Klotho/creatinine ratio were positively correlated with total hospital days and mechanical ventilation days in hospital survivors (Table 3). The median length of hospital stay was 10.5 days (1–63 d) for the 82 patients who survived the hospitalization.

**Correlation Between Study Biomarkers and Biochemical Parameters**

Urine Klotho/creatinine levels were positively correlated with serum calcium, serum albumin, and serum bicarbonate levels (r = 0.047–0.184; p < 0.05) and negatively correlated with serum phosphate and serum magnesium. In contrast, serum intact FGF23 levels were positively correlated with serum phosphate levels (r = 0.379; p < 0.001) and negatively correlated with serum albumin, serum bicarbonate, and arterial pH (Supplementary Fig. 1, Supplemental Digital Content 5, http://links.lww.com/CCX/A56).

**Sensitivity Analyses**

Similar results were obtained when the MAKE-90 definition was modified to the composite of all-cause death, RRT dependence, or the decrease in eGFR of greater than or equal to 25% (rather than 50%) from baseline. In adjusted models, each one-fold higher urine Klotho/creatinine levels was associated with an 83% (95% CI, 60–93%) lower risk of MAKE-90. Each one-fold higher serum intact FGF23 levels was associated with a 110% (95% CI, 26–251%) higher risk of MAKE-90. Similar associations to the primary analysis were observed when biomarker levels were stratified in tertiles (Supplementary Table 5, Supplemental Digital Content 6, http://links.lww.com/CCX/A57).

**DISCUSSION**

The new finding of our study is that both urine Klotho/creatinine and serum intact FGF23 levels associate with MAKE-90 in critically ill patients admitted to the ICU. Specifically, we found that higher urine Klotho/creatinine levels were associated with a decreased risk of MAKE-90, whereas higher serum intact FGF23 levels were associated with an increased risk of MAKE-90 in this subset of critically ill patients. These findings are timely and relevant because increased circulating FGF23 levels (33–35) and reduced Klotho expression (18, 36–38) have been consistently described in experimental models of AKI. Although higher circulating FGF23 levels have been previously associated with human AKI (22, 23) and increased morbidity and mortality in critically ill patients (25, 26, 39), data related to soluble Klotho levels are scarce (40). Our study builds upon evidence that serum intact FGF23 and urine Klotho/creatinine levels may inform novel risk prediction models focusing on renal outcomes in critically ill patients with and without AKI. In addition, our study underpins the relevance of ongoing experimental work targeting therapies to modify circulating levels or downstream effects of FGF23 and Klotho pathways in AKI and critical illness.
Low renal Klotho messenger RNA (mRNA) and protein levels have been described in experimental AKI (18, 36–38). Interestingly, in murine models of post–ischemia-reperfusion injury (IRI) compounded by high-phosphate diet starting 2 weeks after IRI (CKD was detected functionally and histologically ≈22 wk post-IRI), renal Klotho mRNA and protein expression showed a subacute and progressive decline starting at day 14 post-IRI, particularly in mice exposed to prolonged ischemia (41). In the latter model, administration of recombinant Klotho protein given for 4 consecutive days beginning 24 hours after IRI accelerated kidney recovery, reduced kidney fibrosis, enhanced endogenous renal Klotho mRNA and protein expression, and attenuated the occurrence of CKD (41). Multiple mechanisms of Klotho-related renoprotection have been postulated such as suppression of apoptosis (38, 42) and cell senescence (43, 44), antifibrosis (37, 45–48), and up-regulation of autophagy (41, 49) in renal tubular cells.

Elevated plasma FGF23 levels have been reported in murine models of AKI (33–35, 50). Nonetheless, the mechanisms of FGF23 elevation in AKI are not known. Impaired excretion or catabolism of FGF23 by the kidneys or increased production from bone or other organs could be reasonable explanations for this elevation (33–35, 50–52). Measurement of intact FGF23—the biologically active form—is less represented than FGF23 assays with C-terminal reagents (nondiscriminatory between full length and C-terminal fragments) in human AKI literature. Elevation of FGF23 in AKI can augment myofibroblast activation and promote fibrosis via activation of transforming growth factor-β pathways (53).

Data related to urine Klotho measurements in human AKI are scarce. Hu et al (18) demonstrated lower urine Klotho/creatinine

| TABLE 2. Association of Biomarkers With Major Adverse Kidney Event-90 Outcome (Death, Renal Replacement Therapy Dependency, 50% Decrease in Estimated Glomerular Filtration Rate) |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| **Biomarker**   | **Tertile 1**   | **Tertile 2**   | **Tertile 3**   | **Per One-Fold Higher** |
| **Urine Klotho**| **OR (95% CI)** | **OR (95% CI)** | **OR (95% CI)** | **OR (95% CI)**  |
| Range, pM       | ≤ 6.0           | 6.8–21.1        | 22.0–67.4       | 0.52 (0.32–0.87) |
| No. of patients  | 36              | 30              | 33              | 0.52 (0.32–0.87) |
| No. of MAKE-90  | 22              | 9               | 7               | 0.52 (0.32–0.87) |
| Model 1         | 1.00 (Reference)| 0.20 (0.06–0.66)| 0.21 (0.07–0.67)| 0.52 (0.32–0.87) |
| Model 2         | 1.00 (Reference)| 0.23 (0.07–0.82)| 0.21 (0.06–0.71)| 0.52 (0.32–0.87) |

| **Urine Klotho/creatinine** | **OR (95% CI)** | **OR (95% CI)** | **OR (95% CI)** | **OR (95% CI)**  |
| Range, fmol/mg             | ≤ 11.4          | 11.7–21.2       | 22.3–92.8       | 0.17 (0.07–0.39) |
| No. of patients            | 33              | 33              | 33              | 0.17 (0.07–0.39) |
| No. of MAKE-90             | 25              | 10              | 3               | 0.17 (0.07–0.39) |
| Model 1                    | 1.00 (Reference)| 0.18 (0.05–0.56)| 0.04 (0.01–0.19)| 0.17 (0.07–0.39) |
| Model 2                    | 1.00 (Reference)| 0.15 (0.04–0.55)| 0.05 (0.01–0.25)| 0.17 (0.07–0.39) |

| **Serum FGF23** | **OR (95% CI)** | **OR (95% CI)** | **OR (95% CI)** | **OR (95% CI)**  |
| Range, pg/mL     | ≤ 21.5          | 22.5–100.9      | 104.3–4,844.4   | 1.86 (1.17–2.96) |
| No. of patients  | 35              | 36              | 35              | 1.86 (1.17–2.96) |
| No. of MAKE-90   | 6               | 18              | 20              | 1.86 (1.17–2.96) |
| Model 1          | 1.00 (Reference)| 3.74 (1.18–11.79)| 4.30 (1.34–13.84)| 1.86 (1.17–2.96) |
| Model 2          | 1.00 (Reference)| 5.85 (1.62–21.18)| 4.48 (1.29–15.53)| 1.90 (1.17–3.10) |

| **FGF23-to-Klotho/creatinine ratio** | **OR (95% CI)** | **OR (95% CI)** | **OR (95% CI)** | **OR (95% CI)**  |
| Range, log_{e}   | –2.93 to –0.14  | –0.07 to 2.00   | 2.01–6.22       | 2.81 (1.58–5.02) |
| No. of patients  | 33              | 33              | 33              | 2.81 (1.58–5.02) |
| No. of MAKE-90   | 3               | 13              | 22              | 2.81 (1.58–5.02) |
| Model 1          | 1.00 (Reference)| 5.29 (1.29–21.65)| 12.81 (3.03–54.11)| 2.81 (1.58–5.02) |
| Model 2          | 1.00 (Reference)| 6.93 (1.54–31.10)| 11.11 (2.41–51.29)| 2.72 (1.49–4.96) |

FGF = fibroblast growth factor, MAKE = major adverse kidney event, OR = odds ratio.

Model 1: adjust for age, sex, Charlson Comorbidity Index; model 2: adjusted for age, sex, Charlson Comorbidity Index, and nonrenal Acute Physiology and Chronic Health Evaluation II score.
levels in hospitalized AKI patients when compared with healthy volunteers (4.85 ± 1.69 vs 25.38 ± 4.08 fmol/mg of creatinine; p < 0.01). In contrast, Torregrosa et al (54) reported that urine Klotho/creatinine levels were not different in patients with AKI (cardiac surgery or coronary angiography related) versus no AKI. It is important to note that the Klotho assays used were different. Nonetheless, concerns regarding a reliable soluble Klotho assay have precluded large-scale studies (30).

Elevation of plasma FGF23 levels has been described in human AKI (22, 23). In a cohort of 250 adult patients undergoing cardiac surgery, Leaf et al (23) reported that plasma C-terminal FGF23 levels were differentially elevated starting at the end of cardiopulmonary bypass in patients who did versus who did not develop postoperative AKI. In critically ill patients, elevated levels of C-terminal FGF23 have been also reported to be independently associated with incident AKI (26, 39). In a recent post hoc analysis, critically ill patients with the highest versus lowest quartiles of plasma C-terminal and intact FGF23 were found to have higher 60-day mortality (25).

Our study has important strengths that need to be delineated. First, we included patients with well-characterized AKI (KDIGO stage ≥ 2) and controls in the ICU that were matched on clinical parameters that can potentially affect both the independent and dependent variables in the analysis. Second, we used SCr and urine output criteria to define AKI, which is particularly appropriate in the ICU setting. Third, we adjusted our multivariable analyses for appropriate confounders, including objective and comprehensive comorbidity and critical illness scores. Fourth, we measured—for the first time—serum intact FGF23 and urine Klotho/creatinine using paired biospecimens of critically ill patients, which highlights their bidirectional relationship in human AKI and their association with adverse outcomes. Fifth, we measured urine Klotho using a previously reported and validated method that is available and can be replicated (30). Finally, our study tested a relevant 90-day renal outcome which is a recommended endpoint because it relates to the risk of CKD/ESRD post-AKI (32).

Our study also has limitations. First, although our study sample is representative of a heterogeneous ICU population, our study design is also susceptible to selection bias because we included patients with AKI stage greater than or equal to 2 and corresponding matched controls for prespecified clinical characteristics. Further, our sample size is relatively small for the examination of associations of study biomarkers with MAKE-90 according to AKI status. Nonetheless, we did not find a significant interaction between study biomarkers and AKI status for MAKE-90. Second, we did not clinically adjudicate etiology of AKI which can also provide important information for risk stratification of adverse outcome. Third, although we adjusted for confounders by comprehensive comorbidity and critical illness scores, residual confounding by unmeasured covariates may not have been completely eliminated. Finally, our study did not specifically test the utility (performance) of urine Klotho/creatinine or serum intact FGF23 for the prediction of MAKE-90 but identified an important bidirectional relationship between the levels of these biomarkers measured early during the course of ICU admission or AKI diagnosis and subsequent adverse renal outcomes.

### TABLE 3. Associations of Biomarkers With Secondary Outcomes

| Biomarker                  | Outcome     | β (95% CI)     | p    |
|---------------------------|-------------|----------------|------|
| Urine Klotho              | Hospital days | −0.18 (−0.36 to −0.0004) | 0.05 |
|                           | MV days     | −0.62 (−1.05 to −0.19) | 0.005|
| Urine Klotho/creatinine   | Hospital days | −0.27 (−0.47 to −0.08) | 0.006|
|                           | MV days     | −0.98 (−1.57 to −0.38) | 0.002|
| Serum FGF23               | Hospital days | 0.23 (0.13–0.32) | <0.0001|
|                           | MV days     | 0.45 (0.17–0.73) | 0.0001|
| FGF23-to-Klotho/creatinine| Hospital days | 0.17 (0.10–0.25) | <0.0001|
|                           | MV days     | 0.33 (0.13–0.54) | 0.002|

FGF = fibroblast growth factor, MV = mechanical ventilation.

*Hospital survivors only (n = 82).

Model 2: adjusted for age, sex, Charlson Comorbidity Index, and nonrenal Acute Physiology and Chronic Health Evaluation II score.
CONCLUSIONS
Urine Klotho/creatinine levels were significantly lower and serum intact FGF23 levels were significantly higher in critically ill patients with AKI versus matched controls without AKI. When measured in the first 48 hours of ICU admission or AKI diagnosis, urine Klotho/creatinine independently associated with MAKE, particularly in patients with AKI. These results show promise for testing these biomarkers—individually or in combination—as part of novel risk prediction models of renal outcomes in the ICU. Nonetheless, our results need to be validated in a larger sample of critically ill patients with and without AKI to further underpin the impact of Klotho for diagnostics and therapeutics in AKI and critical illness.

REFERENCES
1. Mandelbaum T, Scott DJ, Lee J, et al: Outcome of critically ill patients with acute kidney injury using the acute kidney injury network criteria. Crit Care Med 2011; 39:2659–2664
2. Neyra JA, Manllo J, Li X, et al; AKICI Study Group: Association of de novo dipstick albuminuria with severe acute kidney injury in critically ill septic patients. Nephron Clin Pract 2014; 128:373–380
3. Waikar SS, Liu KD, Chertow GM: Diagnosis, epidemiology and outcomes of acute kidney injury. Clin J Am Soc Nephrol 2008; 3:844–861
4. Lafrance JP, Miller DR: Acute kidney injury associates with increased long-term mortality. J Am Soc Nephrol 2010; 21:345–352
5. Chawla LS, Amdur RL, Amodeo S, et al: The severity of acute kidney injury predicts progression to chronic kidney disease. Kidney Int 2011; 79:1361–1369
6. Coca SG, Singanamala S, Parikh CR: Chronic kidney disease after acute kidney injury predicts progression to chronic kidney disease. Kidney Int 2011; 79:1361–1369
7. Wald R, Quinn RR, Adhikari NK, et al; University of Toronto Acute Kidney Injury Research Group: Risk of chronic dialysis and death following cardiac surgery. Kidney Int 2016; 89:939–948
8. Shi M, Flores B, Gillings N, et al: alphaKlotho mitigates progression of AKI to CKD through activation of autophagy. J Am Soc Nephrol 2015; 27:2331–2345
9. Brown JR, Katz R, Ix JH, et al: Fibroblast growth factor-23 and the long-term risk of hospital-associated AKI among community-dwelling older individuals. Clin J Am Soc Nephrol 2014; 9:239–246
10. Grams ME, Sang Y, Coresh J, et al: Candidate surrogate end points for clinical studies in acute kidney injury? J Am Soc Nephrol 2017; 28:1877–1885
11. Kato Y, Arakawa E, Kinoshita S, et al: Establishment of the anti-klotho antibody 2F12 as a potential biomarker for acute kidney injury. Pediatr Nephrol 2015; 30:1909–1918
12. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group: KDIGO clinical practice guideline for acute kidney injury. Kidney Inter Suppl 2012; 2:1–138
13. Levey AS, Stevens LA, Schmid CH, et al: CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150:604–612
14. Barker SL, Pastor J, Carranza D, et al: The demonstration of αklotho deficiency in human chronic kidney disease with a novel synthetic antibody. Nephrol Dial Transplant 2015; 30:223–233
15. Christov M, Waikar SS, Pereira RC, et al: Plasma FGF23 levels increase rapidly after acute kidney injury. Am J Physiol Renal Physiol 2013; 302:F1252–F1264
16. Sugiura H, Yoshida T, Tsuchiya K, et al: αklotho deficiency is a nonsense-mediated mRNA decay target inefficiently spliced in renal protein. J Am Soc Nephrol 2009; 20:858–859
17. Sugiura H, Yoshida T, Mitobe M, et al: Klotho reduces apoptosis in experimental ischaemic acute kidney injury via HSP-70. Nephrol Dial Transplant 2010; 25:60–68
18. King CD, Chen C, Huang MM, et al: Identification of novel small molecules that elevate klotho expression. Biochem J 2012; 441:453–461
19. Sugiura H, Yoshida T, Mitobe M, et al: Klotho reduces apoptosis in experimental ischaemic acute kidney injury via HSP-70. Nephrol Dial Transplant 2010; 25:60–68
20. King CD, Chen C, Huang MM, et al: Identification of novel small molecules that elevate klotho expression. Biochem J 2012; 441:453–461
21. Shi M, Flores B, Gillings N, et al: alphaKlotho mitigates progression of AKI to CKD through activation of autophagy. J Am Soc Nephrol 2015; 27:2331–2345
22. Brown JR, Katz R, Ix JH, et al: Fibroblast growth factor-23 and the long-term risk of hospital-associated AKI among community-dwelling older individuals. Clin J Am Soc Nephrol 2014; 9:239–246
23. Yeve AS, Stevens LA, Schmid CH, et al: CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150:604–612
24. Barker SL, Pastor J, Carranza D, et al: The demonstration of αklotho deficiency in human chronic kidney disease with a novel synthetic antibody. Nephrol Dial Transplant 2015; 30:223–233
25. Christov M, Waikar SS, Pereira RC, et al: Plasma FGF23 levels increase rapidly after acute kidney injury. Kidney Int 2013; 84:776–785
26. Brown JR, Katz R, Ix JH, et al: Fibroblast growth factor-23 and the long-term risk of hospital-associated AKI among community-dwelling older individuals. Clin J Am Soc Nephrol 2014; 9:239–246
27. Sugiura H, Yoshida T, Tsuchiya K, et al: αklotho deficiency is a nonsense-mediated mRNA decay target inefficiently spliced in renal protein. J Am Soc Nephrol 2009; 20:858–859
28. Sugiura H, Yoshida T, Tsuchiya K, et al: Klotho reduces apoptosis in experimental ischaemic acute kidney injury via HSP-70. Nephrol Dial Transplant 2010; 25:60–68
29. King CD, Chen C, Huang MM, et al: Identification of novel small molecules that elevate klotho expression. Biochem J 2012; 441:453–461
30. Shi M, Flores B, Gillings N, et al: alphaKlotho mitigates progression of AKI to CKD through activation of autophagy. J Am Soc Nephrol 2015; 27:2331–2345
31. Shi M, Flores B, Gillings N, et al: AlphaKlotho mitigates progression of AKI to CKD through activation of autophagy. J Am Soc Nephrol 2015; 27:2331–2345
32. Brown JR, Katz R, Ix JH, et al: Fibroblast growth factor-23 and the long-term risk of hospital-associated AKI among community-dwelling older individuals. Clin J Am Soc Nephrol 2014; 9:239–246
33. Leaf DE, Christov M, Jüppner H, et al: Fibroblast growth factor 23 levels are elevated and associated with severe acute kidney injury and death following cardiac surgery. Kidney Int 2016; 89:939–948
34. Leaf DE, Wolf M, Waikar SS, et al: FGF-23 levels in patients with AKI and risk of adverse outcomes. Clin J Am Soc Nephrol 2012; 7:1217–1223
35. Leaf DE, Siew ED, Eisenga MF, et al: Fibroblast growth factor 23 associates with death in critically ill patients. Clin J Am Soc Nephrol 2018; 13:531–541
36. Leaf DE, Jacob KA, Srivastava A, et al: Fibroblast growth factor 23 levels associate with AKI and death in critical illness. J Am Soc Nephrol 2017; 28:1877–1885
37. Neyra JA, Moe OW, Hu MC: Fibroblast growth factor 23 and acute kidney injury. Pediatr Nephrol 2015; 30:1909–1918
38. Shi M, Flores B, Gillings N, et al: AlphaKlotho mitigates progression of AKI to CKD through activation of autophagy. J Am Soc Nephrol 2015; 27:2331–2345
39. Shi M, Flores B, Gillings N, et al: AlphaKlotho mitigates progression of AKI to CKD through activation of autophagy. J Am Soc Nephrol 2015; 27:2331–2345
40. Neyra JA, Hu MC: Potential application of klotho in human chronic kidney disease. JCI Insight 2017; 2:pii: 94375
41. Shi M, Flores B, Gillings N, et al: AlphaKlotho mitigates progression of AKI to CKD through activation of autophagy. J Am Soc Nephrol 2015; 27:2331–2345
42. Shi M, Flores B, Gillings N, et al: Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 2011; 22:124–136
43. Kuro-o M: Klotho as a regulator of oxidative stress and senescence. *Biol Chem* 2008; 389:233–241

44. Liu F, Wu S, Ren H, et al: Klotho suppresses RIG-I-mediated senescence-associated inflammation. *Nat Cell Biol* 2011; 13:254–262

45. Doi S, Zou Y, Togao O, et al: Klotho inhibits transforming growth factor-beta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice. *J Biol Chem* 2011; 286:8655–8665

46. Zhou L, Li Y, Zhou D, et al: Loss of klotho contributes to kidney injury by derepression of wnt/β-catenin signaling. *J Am Soc Nephrol* 2013; 24:771–785

47. Guan X, Nie L, He T, et al: Klotho suppresses renal tubulo-interstitial fibrosis by controlling basic fibroblast growth factor-2 signalling. *J Pathol* 2014; 234:560–572

48. Huang JS, Chuang CT, Liu MH, et al: Klotho attenuates high glucose-induced fibronectin and cell hypertrophy via the ERK1/2-p38 kinase signaling pathway in renal interstitial fibroblasts. *Mol Cell Endocrinol* 2014; 390:45–53

49. Bian A, Neyra JA, Zhan M, et al: Klotho, stem cells, and aging. *Clin Interv Aging* 2015; 10:1233–1243

50. Mace ML, Gravesen E, Hofman-Bang J, et al: Key role of the kidney in the regulation of fibroblast growth factor 23. *Kidney Int* 2015; 88:1304–1313

51. Hassan A, Durlacher K, Silver J, et al: The fibroblast growth factor receptor mediates the increased FGF23 expression in acute and chronic uremia. *Am J Physiol Renal Physiol* 2016; 310:F217–F221

52. Smith ER, Tan SJ, Holt SG, et al: FGF23 is synthesised locally by renal tubules and activates injury-primed fibroblasts. *Sci Rep* 2017; 7:3345

53. Smith ER, Holt SG, Hewitson TD: FGF23 activates injury-primed renal fibroblasts via FGFR4-dependent signalling and enhancement of TGF-β autoinduction. *Int J Biochem Cell Biol* 2017; 92:63–78

54. Torregrosa I, Montoliu C, Urios A, et al: Urinary klotho measured by ELISA as an early biomarker of acute kidney injury in patients after cardiac surgery or coronary angiography. *Nefrologia* 2015; 35:172–178